Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 19, 2017
Pharmacy Choice - News - Front Page Healthcare News - October 19, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/12/17 - LUPIN ACQUIRES US FIRM SYMBIOMIX FOR $150 MILLION
Pharmaceutical company Lupin has acquired Symbiomix Therapeutics LLC of the US for $150 million, including $50 million as upfront and other time-based payments. There would be other sales-based contingent payments. Lupin previously entered into an option to acquire privately-held Symbiomix, which offers innovative therapies for gynaecological...
10/11/17 - "Evaluating the Paperwork Reduction Act Part II: Are Burdens Being Reduced?"
In addition, FDA promotes the public health by promptly and efficiently reviewing clinical research and taking appropriate action on the marketing of regulated products in a timely manner. FDA also has responsibility for regulating the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco
10/11/17 - 200+ Hospitals Join Premier Inc. Data Sharing Quality Improvement Collaborative
Premier, a healthcare improvement company, issued the following news release:. More than 200 hospitals and health systems have joined Premier Inc.' s QUEST 2020 collaborative to design, test and spread new advances in care delivery across their organizations to improve outcomes and achieve success in value-based payment. A leading healthcare improv
10/11/17 - A Deep Dive Into MannKind's Big Bet On Afrezza
It's been a long road for MannKind Corporation and its Afrezza inhalable insulin product. Here's a look at inhalable insulin's long journey and what the new FDA ruling means for MannKind. At the time, MannKind was already working on Afrezza and submitted an NDA to the FDA on March 16, 2009.
10/11/17 - AbbVie (ABBV), Turnstone Biologics Announce Pact on Viral Immunotherapies in Oncology [Sport360]
AbbVie, a global biopharmaceutical company, and Turnstone Biologics, a clinical-stage immuno-oncology company, today announced a research, option and license agreement whereby AbbVie obtained an exclusive option to license up to three of Turnstone`s next-generation oncolytic viral immunotherapies. This unique approach to cancer treatment...
10/11/17 - Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
ABO-102 Patients Enrolled in Cohort 3 at 3 E13 vg/kg Accelerated enrollments begin with first Patient Enrolled at clinical site in Australia; Patient Screening at Spain site underway Day 30 results demonstrate 67% Heparan sulfate reduction in the CNS and 92% reduction in urinary heparan sulfate and normalization of 76% points in liver volume NEW YO
10/11/17 - Accelerated Path to FDA Approval Subject of Upcoming Panel at CCIT
An alternate path to Food and Drug Administration approval that is gaining popularity will be the focus of a panel discussion on Wednesday, October 18 at the New Jersey Economic Development Authority's Commercialization Center for Innovative Technologies in North Brunswick. Known as the 505 new drug application, this approach to pursuing FDA approv
10/11/17 - Acquisition Of Zevacor Pharma Complete, Rebranding As SOFIE
By a News Reporter-Staff News Editor at Technology News Focus Sofie Biosciences, Inc., the molecular imaging company specializing in novel tools for PET imaging and radiosynthesis of PET compounds, has announced the completion of the acquisition of Zevacor Pharma to form " SOFIE". The addition of Zevacor Pharma's 16 radiopharmacies and Contract..
10/11/17 - Acura Pharmaceuticals Advances LTX - 03 and its LIMITx Technology
Release date- 10102017- PALATINE, Ill.- Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that topline results from clinical study AP-LTX-300 for its LIMITx oral abuse deterrent drug LTX-03 demonstrated rapid release of drug from the micro-particle formulation providing expected...
10/11/17 - Adamas Appoints Mardi C. Dier to its Board of Directors
Adamas Pharmaceuticals, Inc. today announced the appointment of Mardi C. Dier, Chief Financial Officer of Portola Pharmaceuticals, Inc., to its Board of Directors. First, I would like to thank Richard for his years of service to Adamas, during which time we brought Adamas public, financed GOCOVRI? through FDA approval and launch, as well as
10/11/17 - Aerie Pharmaceuticals Announces Appointment of New Members of its Research and Development Team
Release date- 10102017- IRVINE, Calif.- Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first in class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of 11 employees to its Research and Development team located
10/11/17 - Akari Therapeutics Announces Further Clinical Progress
Akari Therapeutics, Plc, a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases, announces that three additional patients have been enrolled in the ongoing Phase II COBALT clinica
10/11/17 - Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China
By a News Reporter-Staff News Editor at Biotech Week Amgen and Simcere Pharmaceutical Group announced the execution of an exclusive agreement to co-develop and commercialize four biosimilars in China. Simcere will be responsible for distribution and commercialization in China, while Amgen will have a limited right to co-promote the products.
10/11/17 - AmpliPhi Biosciences to Participate in Two Upcoming Conferences
AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will present a company overview at two upcoming investor conferences:. AmpliPhi Biosciences Corporation is a clinical-stage...
10/11/17 - ANSM grants authorisation for phase I/II clinical study for retinitis pigmentosa
The French National Agency for Medicines and Health Products Safety is set to launch a Phase I/II clinical trial for HORA-PDE6B, in the treatment of a retinitis pigmentosa...
10/11/17 - Anthem Medicare Plans Achieve Significant 2018 Medicare Star Ratings
Anthem, Inc. is pleased to announce that its Medicare Advantage health plan affiliates have improved their Medicare Star Ratings. The Centers for Medicare and Medicaid Services today released their latest Star Ratings, which give health plans scores for the quality and performance of their services. Over the last four years, Anthem has made a co
10/11/17 - Antihistamine shown to improve function in MS patients
Researchers from the University of California, San Francisco, completed the clinical trial of the U.S. Food and Drug Administration- approved antihistamine clemastine fumarate on patients with MS. The study, published Tuesday in The Lancet, was the first to show a drug is capable of reliably restoring brain function damaged by a neurological diseas
10/11/17 - Arcapita And Mumtalakat Acquire NAS United Healthcare Services
Arcapita, the global alternative investment firm, and Bahrain Mumtalakat Holding Company, the sovereign wealth fund of the Kingdom of Bahrain, have partnered to acquire an approximately 90% stake in NAS United Healthcare Services, a leading GCC provider of outsourced health insurance processing services. NAS provides its customers a comprehensive..
10/11/17 - Arkansas Legislature fails responsibility test
Arkansas Legislature fails responsibility test. This past summer, an Arkansas state legislator claimed that improving or maintaining the Affordable Care Act would have no effect on the state's obesity problem, since health issues, like obesity, reflect lifestyle choices, meaning it's a personal responsibility issue. An example of the "personal...
10/11/17 - ARM, EBE, EFPIA and EuropaBio Jointly Publish Series of Proposals to Streamline Requirements and Accelerate Approvals of Clinical Trials with New...
ARM, EBE, EFPIA and EuropaBio Jointly Publish Series of Proposals to Streamline Requirements and Accelerate Approvals of Clinical Trials with New Therapies Consisting of or Containing Genetically Modified Organisms in Europe. By a News Reporter-Staff News Editor at Biotech Week The Alliance for Regenerative Medicine, the European Biopharmaceutica
10/11/17 - Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek 2017
Release date- 10102017- WALTHAM, Mass. and VIENNA, Austria- Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that the company presented pharmacokinetic data from a Phase 1 clinical trial in healthy volunteers and from a preclinic
10/11/17 - As efforts to sabotage health care continue, Donnelly continues pressing for Administration to 'do no harm' and remains involved in bipartisan Senate negotiations to stabilizing markets
Granger, Ind. Today, U.S. Senator Joe Donnelly again is calling for the Administration to commit to providing stability to health insurance markets and working together on bipartisan solutions to reduce health care costs, expand access to care, and strengthen the health care system. Following up on his previous letter to Hoosier Seema Verma Adm
10/11/17 - AstraZeneca - TAGRISSO granted Breakthrough Therapy Designation by US FDA for the 1stline treatment of patients with EGFR mutation positive non-small cell lung cancer
Release date- 10102017- AstraZeneca today announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for TAGRISSO for the 1st- line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer. Sean Bohen, Executive Vice President, Global Medicines...
10/11/17 - AstraZeneca - The European Medicines Agency accepts marketing authorisation application for Imfinzi in locally-advanced unresectable non-small cell lung cancer
Release date- 10102017- AstraZeneca, along with MedImmune, its global biologics research and development arm, has announced that the European Medicines Agency has accepted a Marketing Authorisation Application for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer whose disease has not progressed...
10/11/17 - At 10.8 % CAGR, Global Generic Drug Market Size & Share Will Reach $380.60 Billion by 2021: Zion Market Research
Zion Market Research has published a new report titled Generic Drug Market by Brand for Central Nervous System, Cardiovascular, Dermatology, Oncology, Respiratory and Others Therapeutic Applications- Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 2021. According to the report, the global generic drug market accoun
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415